Hogarth Communications Inc. Press Releases - EIN Presswire

Published on October 13, 2026 - 11:00 GMT

Jocasta Neuroscience & Diamond Therapeutics to Research Novel Compounds for Cognitive Impairment, Neurodegeneration

Joint research program will evaluate three non-hallucinogenic psychedelic-inspired compounds designed to replicate psilocybin's therapeutic effects TORONTO, ON, CANADA, October 13, 2026 /⁨EINPresswire.com⁩/ -- Jocasta Neuroscience, Inc. (“Jocasta” or …

Distribution channels: Healthcare & Pharmaceuticals Industry, Science ...

Published on July 28, 2026 - 11:15 GMT

Diamond Therapeutics Appoints Dr. Miri Halperin Wernli to its Board of Directors

Global healthcare exec & neuroscientist brings 30+ years leadership in biopharma innovation, neuropsychiatry & advancing science into transformative medicines TORONTO, ON, CANADA, July 28, 2026 /⁨EINPresswire.com⁩/ -- Diamond Therapeutics Inc., a …

Distribution channels: Business & Economy, Healthcare & Pharmaceuticals Industry ...

Published on May 11, 2026 - 12:00 GMT

Diamond Therapeutics Receives Multi-Million Dollar US Government Funding for Phase 2 Clinical Trial of Anxiety Treatment

ARPA-H funding will enable study’s expansion to US as part of Agency’s program to drive development of new, effective therapies for behavioral health BIRMINGHAM, AL, UNITED STATES, May 11, 2026 /⁨EINPresswire.com⁩/ -- Diamond Therapeutics Inc., a clinical …

Distribution channels: Healthcare & Pharmaceuticals Industry ...

Published on April 20, 2026 - 18:09 GMT

Diamond Therapeutics Welcomes White House Executive Order on Research into Psychedelics for Mental Health Treatment

Company now conducting Phase 2 clinical trial using low doses of psilocybin for treatment of generalized anxiety disorder TORONTO, ON, CANADA, April 20, 2026 /⁨EINPresswire.com⁩/ -- Diamond Therapeutics Inc., a clinical-stage drug development company …

Distribution channels: Banking, Finance & Investment Industry, Healthcare & Pharmaceuticals Industry ...